Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study
Cancers · 30.06.2026 · 18 (13) · 2127
DOI: 10.3390/cancers18132127 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.06.2026. Verfasst von Murat Günaltılı und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: The hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been investigated as an immunonutritional biomarker in several solid tumors; however, data in metastatic renal cell carcinoma (mRCC) remain limited. This study aimed to evaluate the prognostic significance of the pretreatment HALP score in patients with mRCC receiving first-line tyrosine kinase inhibitor (TKI) therapy.
Methods
A multicenter retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. HALP was calculated as hemoglobin (g/dL) × albumin (g/dL) × lymphocyte count (×109/L)/platelet count (×109/L). Patients were categorized into HALP-low and HALP-high groups according to the cohort median HALP value.
Results
A total of 1001 patients were enrolled. The median time to treatment failure (TTF) was significantly shorter in the HALP-low group than in the HALP-high group (7.43 months [95% CI 6.4–8.5] vs. 14.26 months [95% CI 12.1–16.4], p < 0.001). The median overall survival (OS) was also significantly shorter in the HALP-low group (30.19 months [95% CI 25.2–35.1] vs. 46.06 months [95% CI 38.2–53.9], p < 0.001). In multivariable analysis, a high HALP score remained independently associated with longer TTF (HR 0.73, 95% CI 0.62–0.86; p < 0.001) and OS (HR 0.69, 95% CI 0.57–0.85; p < 0.001).
Conclusions
The pretreatment HALP score was independently associated with TTF and OS in patients with mRCC treated with first-line TKI therapy. These findings support the prognostic relevance of HALP in this treatment setting and warrant further evaluation of its potential role alongside established clinical risk models.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, 34098 Istanbul, Turkey.
- Department of Medical Oncology, Bilkent City Hospital, 06800 Ankara, Turkey.
- Department of Medical Oncology, Gülhane Training and Research Hospital, University of Health Science, 06010 Ankara, Turkey.
- Department of Medical Oncology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Science, 06200 Ankara, Turkey.
- Department of Medical Oncology, Trakya University School of Medicine, 22030 Edirne, Turkey.
- Department of Medical Oncology, Marmara University School of Medicine, 34899 Istanbul, Turkey.
ORCID-Profile: Murat Günaltılı, Hatice Bölek, Safa Can Efil, Aysun Fatma Akkus, Caner Kapar, Serhat Sekmek, Halil Göksel Güzel, Murad Guliyev, Talha Ozudogru, Sema Sezin Göksu, Özlem Nuray Sever, Mehmet Ali Nahit Sendur, Mustafa Özgüroğlu, Emre Yekedüz, Yüksel Ürün
Zitieren
APA
Günaltılı, M., Bölek, H., Kaplan Tüzün, E., Usta, S., Efil, S. C., Akkus, A. F., Işık, S., Kapar, C., Sekmek, S., Güzel, H. G., Guliyev, M., Ozudogru, T., Göksu, S. S., Sever, Ö. N., Arslan, Ç., Karadurmuş, N., Sendur, M. A. N., Tural, D., Özgüroğlu, M., …, & Ürün, Y. (2026). Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study. Cancers, 18(13), 2127. https://doi.org/10.3390/cancers18132127
Vancouver
Günaltılı M, Bölek H, Kaplan Tüzün E, Usta S, Efil SC, Akkus AF, et al. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study. Cancers. 2026;18(13):2127. doi:10.3390/cancers18132127
BibTeX
@article{Gnaltl2026,
author = {Günaltılı, Murat and Bölek, Hatice and Kaplan Tüzün, Esma and Usta, Sura and Efil, Safa Can and Akkus, Aysun Fatma and Işık, Selver and Kapar, Caner and Sekmek, Serhat and Güzel, Halil Göksel and Guliyev, Murad and Ozudogru, Talha and Göksu, Sema Sezin and Sever, Özlem Nuray and Arslan, Çagatay and Karadurmuş, Nuri and Sendur, Mehmet Ali Nahit and Tural, Deniz and Özgüroğlu, Mustafa and Yekedüz, Emre and Ürün, Yüksel},
title = {Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2127},
doi = {10.3390/cancers18132127}
}
EUVIMED